Axio Biosolutions announces world-class Scientific Advisory Board
Dr Shiladitya Sengupta from Harvard Medical School joins as Chairman of the board along with Dr S V Mahadevan from Stanford University Medical as member of the board
Axio Biosolutions, med-tech company is all set to step up its US launch plans with the announcement of its top-notch Scientific Advisory Board.
The Bengaluru-based enterprise has appointed Dr Shiladitya Sengupta, Assistant Professor of Medicine at Harvard Medical School, as Chairman, and Dr S V Mahadevan, Professor of Emergency Medicine at Stanford University, as member of its Scientific Advisory Board. The appointments are a testament to Axio’s unwavering commitment to bring the latest scientific and technological innovation into the wound care and surgical market.
An alumnus of the All India Institute of Medical Sciences, where he received the Geeta Mital Gold Medal, Dr Sengupta serves as Assistant Professor of Health Sciences and Technology at MIT, and principal investigator at the Dana- Farber Cancer Institute, Boston. After completing his PhD at Trinity College, University of Cambridge (where he was a Nehru Scholar as well as a British Chevening Scholar) and a fellowship in Biological Engineering from MIT, Dr Sengupta joined the Harvard faculty.
The co-founder of Akamara Therapeutics (hitherto Invictus Oncology), Vyome Biosciences, Mitra Biotech and Cerulean Pharma (served on the Scientific Advisory Board), Dr Sengupta, has also co-chaired the Center for Regenerative Medicine at the Brigham and Women’s Hospital in Boston. He has been the recipient of several prestigious awards, including the TR35 Innovator Award by MIT Technology Review magazine; the Era of Hope Scholar Award and the Innovator Collaborative Award from the US Department of Defense; the Coulter Foundation Career Award; and the Shakuntala Amir Chand Award from the Indian Council for Medical Research.
Axio’s other notable appointment, Dr S V Mahadevan, Professor of Emergency Medicine at Stanford University, Palo Alto, California, brings critical expertise of over 23 years in emergency medicine to the Scientific Advisory Board. The founding chair of the Department of Emergency Medicine at Stanford (2015-17) and founding Director of Stanford Emergency Medicine International (2000-2015), Dr Mahadevan currently serves as both the Director of Global Affairs and Strategy for Stanford Medicine as well as the Director of South Asia Outreach, Center for Asian Health Research and Education (CARE).
Dr Mahadevan has received numerous esteemed teaching awards throughout his illustrious career, and is the lead editor of the textbook, An Introduction to Clinical Emergency Medicine, which won the 2006 American Medical Writer’s Association Award in the Physician’s Category. Currently, he is a teaching physician at Stanford Health Care.
Commenting on the momentous appointments, Leo Mavely, CEO of Axio Biosolutions, said, “We are delighted and honoured to welcome Dr Sengupta and Dr Mahadevan onboard. While Dr Sengupta is a serial entrepreneur and inventor of over 350 pending/granted patents, with more than 100 papers published in scientific journals, Dr Mahadevan’s expertise in emergency medicine is unparalleled. We hope to leverage the rich expertise of our Scientific Advisory Board to support Axio’s vision of building Indian innovation in wound care and surgical care for the world market.”
Dr Sengupta remarked, “There are not many technological innovations happening in the advanced biomaterial space, not just in India, but across the globe. Axio has proven to be a leader in this space through its technological innovations and has the potential to be a real game changer. I’m excited to be a part of the team that is well positioned to disrupt surgical and wound care markets worldwide.
Dr Mahadevan further added, “I was truly impressed by the ingenuity and enthusiasm of Axio’s close-knit team. I am so excited to collaborate with them in developing affordable and innovative approaches for the treatment of emergency bleeding, which claims so many innocent lives across the world. Their focus on high-impact, world-class products for treating hemorrhage in trauma and maternal care could save millions of lives each year.”
Catering to the Indian Armed Forces, BSF, NSG, para-military forces, hospitals and emergency services not only in India, but across the globe, the home-grown first aid solution has prevented countless deaths due to haemorrhage and grievous injuries. Axio offers a complete range of innovative products spanning pre-hospital, intra-operative and post-operative clinical needs.
Last year, Axio raised $7.4 million in a Series B funding round led by Ratan Tata’s UC- RNT, along with existing investors Accel Partners and IDG Ventures India. Headquartered in Boston, the med-tech company has its corporate office in Bengaluru. Axiostat is currently manufactured at GMP, ISO 13485-certified manufacturing facility in Gujarat. The company has built a strong R&D structure, with multiple patents to its credit in the wound healing, mucoadhesive drug delivery and hemostats space.